论文部分内容阅读
多发性骨髓瘤(MM)是一种以单克隆浆细胞(骨髓瘤细胞)在骨髓内聚集同时产生单克隆性Ig(M成分)为特征的肿瘤性疾患。近5、6年来对肿瘤细胞的起源与扩散、增殖与分化及新的治疗方法的研究有诸多新的观点,本文就此作简要综述。一、肿瘤细胞的起源与扩散 骨髓瘤虽然是产生、分泌Ig的浆细胞的肿瘤性疾患,但从其分化抗原的分析资料看,骨髓瘤细胞来源于未分化的pre-B细胞,由此推测肿瘤化过程是从造血干细胞水平→未分化Pre-B细胞～[1]。 从骨髓瘤细胞表面高频度检出各造血系的未分化抗原有:B细胞抗原(CD9、CD10、CD20、HLA-DR、sIg)、NK细胞抗原(CD56等)、T细胞抗原(CD2、CD4)及骨髓瘤细胞抗原(CD13、CD14、CD15、CD33、CD41a、CD45R及血型糖蛋白A等)。
Multiple myeloma (MM) is a neoplastic disorder characterized by the aggregation of monoclonal plasma cells (myeloma cells) in the bone marrow while producing monoclonal Ig (M component). There have been many new perspectives on the origin and proliferation, proliferation and differentiation of tumor cells and new therapeutic methods in the past 5 or 6 years. This article briefly reviews this topic. First, the origin and proliferation of tumor cells Although myeloma is a neoplastic disease that produces and secretes Ig plasma cells, from the analysis of differentiation antigens, myeloma cells are derived from undifferentiated pre-B cells. The process of tumorization is from the level of hematopoietic stem cells → undifferentiated Pre-B cells ~ [1]. The undifferentiated antigens of each hematopoietic system detected from the surface of myeloma cells at high frequency include B cell antigens (CD9, CD10, CD20, HLA-DR, sIg), NK cell antigens (CD56, etc.), and T cell antigens (CD2). CD4) and myeloma cell antigens (CD13, CD14, CD15, CD33, CD41a, CD45R, glycophorin A, etc.).